Literature DB >> 19037054

ACOG Practice Bulletin No. 99: management of abnormal cervical cytology and histology.

.   

Abstract

Recent evidence has shown that the risk of malignant and premalignant cervical disease and human papillomavirus (HPV) infections varies significantly with age (1,2). Furthermore, evidence now shows that treatment for cervical disease carries significant risk for future pregnancies (3-7). These factors have led to a re-evaluation of the guidelines for the management of premalignant cervical disease. The purpose of this document is to define strategies for diagnosis and management of abnormal cervical cytology and histology results. In this document, HPV refers to high-risk oncogenic forms of the virus.

Entities:  

Mesh:

Year:  2008        PMID: 19037054     DOI: 10.1097/AOG.0b013e318192497c

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  16 in total

1.  Policy implications of adjusting randomized trial data for economic evaluations: a demonstration from the ASCUS-LSIL Triage Study.

Authors:  Nicole G Campos; Philip E Castle; Mark Schiffman; Jane J Kim
Journal:  Med Decis Making       Date:  2011-12-06       Impact factor: 2.583

2.  Performance of implementing guideline-driven cervical cancer screening measures in an inner-city hospital system.

Authors:  Daryl L Wieland; Laura L Reimers; Eijean Wu; Lisa M Nathan; Tammy Gruenberg; Maria Abadi; Mark H Einstein
Journal:  J Low Genit Tract Dis       Date:  2011-10       Impact factor: 1.925

3.  The impact of liquid-based cytology in decreasing the incidence of cervical cancer.

Authors:  Randall K Gibb; Mark G Martens
Journal:  Rev Obstet Gynecol       Date:  2011

4.  Lessons from practice: risk of CIN 3 or cancer associated with an LSIL or HPV-positive ASC-US screening result in women aged 21 to 24.

Authors:  Gaea Moore; Barbara Fetterman; J Thomas Cox; Nancy Poitras; Thomas Lorey; Walter Kinney; Philip E Castle
Journal:  J Low Genit Tract Dis       Date:  2010-04       Impact factor: 1.925

5.  Increase in viral load, viral integration, and gain of telomerase genes during uterine cervical carcinogenesis can be simultaneously assessed by the HPV 16/18 MLPA-assay.

Authors:  Wendy Theelen; Ernst-Jan M Speel; Michael Herfs; Martin Reijans; Guus Simons; Els V Meulemans; Marcella M Baldewijns; Frans C S Ramaekers; Joan Somja; Philippe Delvenne; Anton H N Hopman
Journal:  Am J Pathol       Date:  2010-09-02       Impact factor: 4.307

Review 6.  Early cervical neoplasia: advances in screening and treatment modalities.

Authors:  Brent Tierney; Shannon N Westin; Matthew P Schlumbrecht; Pedro T Ramirez
Journal:  Clin Adv Hematol Oncol       Date:  2010-08

7.  Comparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions.

Authors:  Julia C Gage; Mark Schiffman; Diane Solomon; Cosette M Wheeler; Philip E Castle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07       Impact factor: 4.254

8.  Preferences for surveillance strategies for women treated for high-grade precancerous cervical lesions.

Authors:  M Kuppermann; J Melnikow; C Slee; D J Tancredi; S Kulasingam; S Birch; L J Helms; A M Bayoumi; G F Sawaya
Journal:  Gynecol Oncol       Date:  2010-08-01       Impact factor: 5.482

9.  Detection of cervical cancer and its precursors by endocervical curettage in 13,115 colposcopically guided biopsy examinations.

Authors:  Julia C Gage; Máire A Duggan; Jill G Nation; Song Gao; Philip E Castle
Journal:  Am J Obstet Gynecol       Date:  2010-08-30       Impact factor: 8.661

10.  Development of Low-Cost Point-of-Care Technologies for Cervical Cancer Prevention Based on a Single-Board Computer.

Authors:  Sonia Parra; Eduardo Carranza; Jackson Coole; Brady Hunt; Chelsey Smith; Pelham Keahey; Mauricio Maza; Kathleen Schmeler; Rebecca Richards-Kortum
Journal:  IEEE J Transl Eng Health Med       Date:  2020-02-03       Impact factor: 3.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.